The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors.

Autor: Mete O; Department of Pathology, University Health Network, Toronto General Hospital, 200 Elizabeth Street, 11th floor, Toronto, ON, Canada, M5G 2C4. ozgur.mete2@uhn.ca.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. ozgur.mete2@uhn.ca.; Endocrine Oncology Site, Princess Margaret Cancer Centre, Toronto, ON, Canada. ozgur.mete2@uhn.ca., Dodington DW; Department of Pathology, University Health Network, Toronto General Hospital, 200 Elizabeth Street, 11th floor, Toronto, ON, Canada, M5G 2C4.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Shen DL; Department of Pathology, Institute of Pathology, University Hospitals Cleveland, Case Western Reserve University, 11100 Euclid Avenue, Room 204, Cleveland, OH, 44106, USA.; Department of Pathology, University of Texas Southwestern, Dallas, TX, USA., Asa SL; Department of Pathology, Institute of Pathology, University Hospitals Cleveland, Case Western Reserve University, 11100 Euclid Avenue, Room 204, Cleveland, OH, 44106, USA. Pathlady01@gmail.com.
Jazyk: angličtina
Zdroj: Endocrine pathology [Endocr Pathol] 2024 Jun; Vol. 35 (2), pp. 107-112. Date of Electronic Publication: 2024 Jun 04.
DOI: 10.1007/s12022-024-09813-4
Abstrakt: Appendiceal neuroendocrine tumors (NETs) are common and often are identified as incidental lesions at the time of appendectomy. The guidelines for management are based on tumor size, degree of invasion, and the Ki67 proliferation index. Most small bowel NETs are composed of serotonin-producing EC-cells, but there are multiple other neuroendocrine cell types. In the rectum, there are L-cell tumors that express peptide YY (PYY), glucagon-like peptides (GLPs), and pancreatic polypeptide (PP); they are thought to have a better prognosis than serotonin-producing tumors. We investigated whether the appendix has distinct neuroendocrine tumor types based on cell type and whether that distinction has clinical significance. We collected 135 appendiceal NETs from the pathology archives of UHN Toronto and UHCMC (Cleveland). We analyzed the expression of biomarkers including CDX2, SATB2, PSAP, serotonin, glucagon (that detects GLPs), PYY, and pancreatic polypeptide (PP) and correlated the results with clinicopathologic parameters. Immunohistochemistry identified three types of appendiceal NETs. There were 75 (56%) classified as EC-cell tumors and 37 (27%) classified as L-cell tumors; the remaining 23 (17%) expressed serotonin and one of the L-cell biomarkers and were classified as mixed. EC-cell tumors were significantly larger with more extensive invasion involving the muscularis propria, subserosa, and mesoappendix compared with L-cell tumors. Mixed tumors were intermediate in all of these parameters. Both EC-cell and mixed tumors had lymphatic and/or vascular invasion while L-cell tumors had none. Unlike EC-cell NETs, L-cell tumors were not associated with lymph node metastasis. Tumor type correlated with pT stage and the only patient with distant metastatic disease in this series had an EC-cell tumor. Our study confirms that appendiceal NETs are not a homogeneous tumor population. There are at least three types of appendiceal NET, including EC-cell, L-cell, and mixed tumors. This information is important for surveillance of patients, as monitoring urinary 5HIAA levels is only appropriate for patients with serotonin-producing tumors, whereas measurement of GLPs and/or PP is more appropriate for patients with L-cell tumors. Our data also show that tumor type is of significance with EC-cell tumors exhibiting the most aggressive behavior.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: